Cargando…
Pathogenic implications of cerebrospinal fluid barrier pathology in neuromyelitis optica
Pathogenic autoantibodies associated with neuromyelitis optica (NMO) induce disease by targeting aquaporin-4 (AQP4) water channels enriched on astrocytic endfeet at blood–brain interfaces. AQP4 is also expressed at cerebrospinal fluid (CSF)–brain interfaces, such as the pial glia limitans and the ep...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5348570/ https://www.ncbi.nlm.nih.gov/pubmed/28184993 http://dx.doi.org/10.1007/s00401-017-1682-1 |
_version_ | 1782514259226263552 |
---|---|
author | Guo, Yong Weigand, Stephen D. Popescu, Bogdan F. Lennon, Vanda A. Parisi, Joseph E. Pittock, Sean J. Parks, Natalie E. Clardy, Stacey L. Howe, Charles L. Lucchinetti, Claudia F. |
author_facet | Guo, Yong Weigand, Stephen D. Popescu, Bogdan F. Lennon, Vanda A. Parisi, Joseph E. Pittock, Sean J. Parks, Natalie E. Clardy, Stacey L. Howe, Charles L. Lucchinetti, Claudia F. |
author_sort | Guo, Yong |
collection | PubMed |
description | Pathogenic autoantibodies associated with neuromyelitis optica (NMO) induce disease by targeting aquaporin-4 (AQP4) water channels enriched on astrocytic endfeet at blood–brain interfaces. AQP4 is also expressed at cerebrospinal fluid (CSF)–brain interfaces, such as the pial glia limitans and the ependyma and at the choroid plexus blood–CSF barrier. However, little is known regarding pathology at these sites in NMO. Therefore, we evaluated AQP4 expression, microglial reactivity, and complement deposition at pial and ependymal surfaces and in the fourth ventricle choroid plexus in 23 autopsy cases with clinically and/or pathologically confirmed NMO or NMO spectrum disorder. These findings were compared to five cases with multiple sclerosis, five cases of choroid plexus papilloma, and five control cases without central nervous system disease. In the NMO cases, AQP4 immunoreactivity was reduced relative to control levels in the pia (91%; 21/23), ependyma (56%; 9/16), and choroid plexus epithelium (100%; 12/12). AQP4 immunoreactivity was normal in MS cases in these regions. Compared to MS, NMO cases also showed a focal pattern of pial and ependymal complement deposition and more pronounced microglial reactivity. In addition, AQP4 loss, microglial reactivity, and complement deposition colocalized along the pia and ependyma only in NMO cases. Within the choroid plexus, AQP4 loss was coincident with C9neo immunoreactivity on epithelial cell membranes only in NMO cases. These observations demonstrate that NMO immunopathology extends beyond perivascular astrocytic foot processes to include the pia, ependyma, and choroid plexus, suggesting that NMO IgG-induced pathological alterations at CSF–brain and blood–CSF interfaces may contribute to the occurrence of ventriculitis, leptomeningitis, and hydrocephalus observed among NMO patients. Moreover, disruption of the blood–CSF barrier induced by binding of NMO IgG to AQP4 on the basolateral surface of choroid plexus epithelial cells may provide a unique portal for entry of the pathogenic antibody into the central nervous system. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s00401-017-1682-1) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-5348570 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-53485702017-03-27 Pathogenic implications of cerebrospinal fluid barrier pathology in neuromyelitis optica Guo, Yong Weigand, Stephen D. Popescu, Bogdan F. Lennon, Vanda A. Parisi, Joseph E. Pittock, Sean J. Parks, Natalie E. Clardy, Stacey L. Howe, Charles L. Lucchinetti, Claudia F. Acta Neuropathol Original Paper Pathogenic autoantibodies associated with neuromyelitis optica (NMO) induce disease by targeting aquaporin-4 (AQP4) water channels enriched on astrocytic endfeet at blood–brain interfaces. AQP4 is also expressed at cerebrospinal fluid (CSF)–brain interfaces, such as the pial glia limitans and the ependyma and at the choroid plexus blood–CSF barrier. However, little is known regarding pathology at these sites in NMO. Therefore, we evaluated AQP4 expression, microglial reactivity, and complement deposition at pial and ependymal surfaces and in the fourth ventricle choroid plexus in 23 autopsy cases with clinically and/or pathologically confirmed NMO or NMO spectrum disorder. These findings were compared to five cases with multiple sclerosis, five cases of choroid plexus papilloma, and five control cases without central nervous system disease. In the NMO cases, AQP4 immunoreactivity was reduced relative to control levels in the pia (91%; 21/23), ependyma (56%; 9/16), and choroid plexus epithelium (100%; 12/12). AQP4 immunoreactivity was normal in MS cases in these regions. Compared to MS, NMO cases also showed a focal pattern of pial and ependymal complement deposition and more pronounced microglial reactivity. In addition, AQP4 loss, microglial reactivity, and complement deposition colocalized along the pia and ependyma only in NMO cases. Within the choroid plexus, AQP4 loss was coincident with C9neo immunoreactivity on epithelial cell membranes only in NMO cases. These observations demonstrate that NMO immunopathology extends beyond perivascular astrocytic foot processes to include the pia, ependyma, and choroid plexus, suggesting that NMO IgG-induced pathological alterations at CSF–brain and blood–CSF interfaces may contribute to the occurrence of ventriculitis, leptomeningitis, and hydrocephalus observed among NMO patients. Moreover, disruption of the blood–CSF barrier induced by binding of NMO IgG to AQP4 on the basolateral surface of choroid plexus epithelial cells may provide a unique portal for entry of the pathogenic antibody into the central nervous system. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s00401-017-1682-1) contains supplementary material, which is available to authorized users. Springer Berlin Heidelberg 2017-02-09 2017 /pmc/articles/PMC5348570/ /pubmed/28184993 http://dx.doi.org/10.1007/s00401-017-1682-1 Text en © The Author(s) 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Original Paper Guo, Yong Weigand, Stephen D. Popescu, Bogdan F. Lennon, Vanda A. Parisi, Joseph E. Pittock, Sean J. Parks, Natalie E. Clardy, Stacey L. Howe, Charles L. Lucchinetti, Claudia F. Pathogenic implications of cerebrospinal fluid barrier pathology in neuromyelitis optica |
title | Pathogenic implications of cerebrospinal fluid barrier pathology in neuromyelitis optica |
title_full | Pathogenic implications of cerebrospinal fluid barrier pathology in neuromyelitis optica |
title_fullStr | Pathogenic implications of cerebrospinal fluid barrier pathology in neuromyelitis optica |
title_full_unstemmed | Pathogenic implications of cerebrospinal fluid barrier pathology in neuromyelitis optica |
title_short | Pathogenic implications of cerebrospinal fluid barrier pathology in neuromyelitis optica |
title_sort | pathogenic implications of cerebrospinal fluid barrier pathology in neuromyelitis optica |
topic | Original Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5348570/ https://www.ncbi.nlm.nih.gov/pubmed/28184993 http://dx.doi.org/10.1007/s00401-017-1682-1 |
work_keys_str_mv | AT guoyong pathogenicimplicationsofcerebrospinalfluidbarrierpathologyinneuromyelitisoptica AT weigandstephend pathogenicimplicationsofcerebrospinalfluidbarrierpathologyinneuromyelitisoptica AT popescubogdanf pathogenicimplicationsofcerebrospinalfluidbarrierpathologyinneuromyelitisoptica AT lennonvandaa pathogenicimplicationsofcerebrospinalfluidbarrierpathologyinneuromyelitisoptica AT parisijosephe pathogenicimplicationsofcerebrospinalfluidbarrierpathologyinneuromyelitisoptica AT pittockseanj pathogenicimplicationsofcerebrospinalfluidbarrierpathologyinneuromyelitisoptica AT parksnataliee pathogenicimplicationsofcerebrospinalfluidbarrierpathologyinneuromyelitisoptica AT clardystaceyl pathogenicimplicationsofcerebrospinalfluidbarrierpathologyinneuromyelitisoptica AT howecharlesl pathogenicimplicationsofcerebrospinalfluidbarrierpathologyinneuromyelitisoptica AT lucchinetticlaudiaf pathogenicimplicationsofcerebrospinalfluidbarrierpathologyinneuromyelitisoptica |